At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 136 enrolled
Drug / intervention
Otrivine Congestion Reliefdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Real-World Evidence Study Evaluating Quality of Life Parameters Following Treatment With Otrivine (Xylometazoline Hydrochloride)
In Brief
A Phase 4 clinical trial evaluating Otrivine Congestion Relief for Common Cold. Completed, enrolled 136 participants across 1 site.
Detailed Summary
This study is designed to generate real world data from participants with nasal congestion acquired from common cold following treatment with a marketed nasal spray. The main purpose of this study is to evaluate the effectiveness of a nasal spray on quality of life (QoL) factors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCommon Cold
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 4CompletedFinished
2023202420252026
First PostedSep 2022
Enrollment StartNov 2022
Primary CompletionDec 2022
TodayJul 2026
First PostedSep 27, 2022
Enrollment StartNov 7, 2022
Primary CompletionDec 20, 2022
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 3.8 years ago
Interventions
Otrivine Congestion Reliefdrug
0.1% Nasal Spray (Xylometazoline Hydrochloride)